ElevateBio Company Overview
ElevateBio is a biotechnology company focused on enabling cell and gene therapies. It operates BaseCamp, a network of cGMP facilities that provide viral vector, cell therapy, and gene editing capabilities along with process and analytical services. The company partners with biopharma and academic groups and also builds and supports portfolio companies to advance programs in oncology, rare diseases, and regenerative medicine. Its technology platforms span AAV and lentiviral vectors, iPSC, CAR and TCR cell therapies, and integrated CMC, digital, and automation tools to scale production. ElevateBio offers end-to-end support from research translation through process optimization, manufacturing strategy, quality, and regulatory guidance to enable clinical and commercial supply.
New to Pre-IPO Investing?
Get smarter about private markets and Pre-IPO investing:
- Get key practice tips for private-market investing
- Understand how to evaluate deal terms and common structures
- Evaluate fees and their impact on returns
- Develop a thesis and underwrite your investment
- Learn common pitfalls first-time investors face
FAQ
Does ElevateBio have stock?
Yes, ElevateBio and almost all privately held companies issue stock so founders, employees, and investors can participate in equity ownership. However, because ElevateBio is privately held, it is more challenging to acquire shares than if the company was publicly traded.
Is ElevateBio publicly traded?
No, ElevateBio is a privately held company. It is not publicly traded or offered directly on any stock exchange like the NYSE, Nasdaq, etc.
Who owns ElevateBio stock?
As a privately held company, ElevateBio shares are held by its founders, management, employees, venture capital funds, or other private individuals and institutional investors.
Disclosure rules differ for private and public companies, so it may not always be possible to know the complete ownership (cap table) of a private company like ElevateBio.
What is the stock symbol for ElevateBio?
ElevateBio is a privately held company. Therefore, it does not have a stock symbol or “ticker” that trades on public exchanges like the NYSE, Nasdaq, etc.
Can I buy ElevateBio shares on UpMarket?
If you would like to buy shares in ElevateBio, please provide your information in the form at the top of this page and click the button titled “I want to buy this stock.”
One of our investor relations team members will contact you to discuss ElevateBio stock availability. Note: inquiries are non-binding, subject to market availability, and shares may only be purchased by accredited investors that meet all eligibility criteria.
UpMarket has offered many similar companies as Pre-IPO investments, including Airbnb, SpaceX, ByteDance, Plaid, Kraken, Databricks, and others. UpMarket also often has funds available that invest in a portfolio of companies potentially including, ElevateBio as well.
What is ElevateBio stock price?
The stock price of ElevateBio can be calculated by taking the valuation of the company divided by the number of shares outstanding. Because a private company can issue new shares at any time, we do not know the current number of shares outstanding.
How do ElevateBio pre-IPO trades work?
Pre-IPO trades for ElevateBio will typically involve accredited investors purchasing shares from current shareholders through specialized investment platforms like UpMarket. Trades generally occur on the secondary market, meaning ElevateBio doesn't issue new shares or receive capital–shares are privately exchanged between two parties.
While investors aim to profit from a potential IPO or acquisition, these investments carry high risks due to limited liquidity and information. Understanding all terms and conditions is crucial, as each transaction can have unique characteristics. Investing in private companies can be extremely risky and may result in significant capital loss.
When is ElevateBio going to go public?
The decision to go public through an Initial Public Offering (IPO) is complex and depends on various factors, including the company's financial performance, market conditions, and strategic goals.
Unless ElevateBio officially announces its intention to go public, any predictions about when or if it will do so would be speculative.
Investors interested in ElevateBio should monitor official company communications and reliable financial news sources for any updates regarding potential IPO plans.
How do I exit my investment if I invest in ElevateBio with UpMarket?
Exiting your investment in ElevateBio typically involves one of these scenarios: 1) selling your shares on a secondary market to other interested investors; 2) holding shares until a liquidity event occurs, such as the company going public (IPO) or being acquired.
Investors must know that the timing and availability of these exit options are inherently unpredictable, and there is no guarantee of when or if they will occur.
How can I sell ElevateBio shares?
If you own ElevateBio shares, you may be able to find a buyer on a pre-IPO marketplace or via an introduction by a registered broker-dealer like UpMarket. It is important to note that the class of shares you own may impact your ability to sell. For example, shares issued to startup employees often have transaction limitations, including lock-up periods and a right of first refusal by the company, which may prevent you from selling your shares freely.
How does UpMarket estimate the valuation of ElevateBio?
UpMarket’s valuation estimate for ElevateBio is algorithmically generated based on recent primary round financings by ElevateBio, market conditions, company popularity, sector performance, and public market comps.
It is important to note that UpMarket’s valuation estimate for ElevateBio could be outdated, may not reflect all recent news or market events, and is not intended to inform any investment decision-making. UpMarket’s valuation estimate is not meant to be a warranty or projection of potential financial returns or company performance. Valuations can change rapidly and unexpectedly.
Why choose UpMarket?
Founded in 2019, UpMarket has brokered over $500 million in alternative investments for more than 1000 investors, including principal invested and appreciation as of September 30, 2025. These investments span pre-IPO companies, hedge funds, private equity, real estate, and other alternative assets. Approximately $122 million is managed by UpMarket Management, with the remainder managed by affiliates. Past performance is not predictive of future results. UpMarket is a licensed broker-dealer based in the United States.
If you are an accredited investor, you can create a free account to access our deal flow and opportunities. There is never any pressure to invest.
UpMarket clients have invested in companies like
ElevateBio,
SpaceX, Neuralink, Anthropic, and many others. UpMarket and its leadership have been mentioned in media outlets like Forbes, WealthManagement, Wealth and Finance News, and TechBullion.
ElevateBio Management
| Name | Position |
|---|---|
| David Hallal | CEO |
| Mitchell Finer | CSO |
| Vikas Sinha | CFO |
